Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Reid

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Thrombolysis|November 6, 2007
Optical density values correlate with the clinical probability of heparin induced thrombocytopeniaBrendan M Weiss, Nathan M Shumway, Robin S Howard, et al.
Transfusion|February 14, 2004
New insulation technology provides next-generation containers for "iceless" and lightweight transport of RBCs at 1 to 10 degrees C in extreme temperatures for over 78 hoursFrancisco J Rentas, Victor W Macdonald, Delories M Houchens, et al.
Journal of Liposome Research|December 13, 2003
The interaction of DMSO with model membranes. I. Comparison of DMSO and d6-DMSO: a DSC and IR investigationCarla J Long, Peter J Hmel, Anthony Kennedy, et al.
Critical Care Medicine|July 18, 2008
Massive transfusion and nonsurgical hemostatic agentsJeremy G Perkins, Andrew P Cap, Brendan M Weiss, et al.
The Journal of Trauma|August 13, 2005
A salmon thrombin-fibrin bandage controls arterial bleeding in a swine aortotomy modelStephen W Rothwell, Thomas J Reid, Jennifer Dorsey, et al.
The New England Journal of Medicine|February 21, 2014
Improved survival with bevacizumab in advanced cervical cancerKrishnansu S Tewari, Michael W Sill, Harry J Long, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
The Journal of Trauma|September 23, 2003
Advanced hemostatic dressing development program: animal model selection criteria and results of a study of nine hemostatic dressings in a model of severe large venous hemorrhage and hepatic injury in SwineAnthony E Pusateri, Harold E Modrow, Richard A Harris, et al.
Gynecologic Oncology|December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyElizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Thrombolysis|November 6, 2007
Optical density values correlate with the clinical probability of heparin induced thrombocytopeniaBrendan M Weiss, Nathan M Shumway, Robin S Howard, et al.
Transfusion|February 14, 2004
New insulation technology provides next-generation containers for "iceless" and lightweight transport of RBCs at 1 to 10 degrees C in extreme temperatures for over 78 hoursFrancisco J Rentas, Victor W Macdonald, Delories M Houchens, et al.
Journal of Liposome Research|December 13, 2003
The interaction of DMSO with model membranes. I. Comparison of DMSO and d6-DMSO: a DSC and IR investigationCarla J Long, Peter J Hmel, Anthony Kennedy, et al.
Critical Care Medicine|July 18, 2008
Massive transfusion and nonsurgical hemostatic agentsJeremy G Perkins, Andrew P Cap, Brendan M Weiss, et al.
The Journal of Trauma|August 13, 2005
A salmon thrombin-fibrin bandage controls arterial bleeding in a swine aortotomy modelStephen W Rothwell, Thomas J Reid, Jennifer Dorsey, et al.
The New England Journal of Medicine|February 21, 2014
Improved survival with bevacizumab in advanced cervical cancerKrishnansu S Tewari, Michael W Sill, Harry J Long, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
The Journal of Trauma|September 23, 2003
Advanced hemostatic dressing development program: animal model selection criteria and results of a study of nine hemostatic dressings in a model of severe large venous hemorrhage and hepatic injury in SwineAnthony E Pusateri, Harold E Modrow, Richard A Harris, et al.
Gynecologic Oncology|December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyElizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 3